Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $210.0 million.

  • Assembly Biosciences' Short-term Investments rose 21581.46% to $210.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $210.0 million, marking a year-over-year increase of 21581.46%. This contributed to the annual value of $73.7 million for FY2024, which is 3321.47% down from last year.
  • Assembly Biosciences' Short-term Investments amounted to $210.0 million in Q3 2025, which was up 21581.46% from $51.0 million recorded in Q2 2025.
  • Assembly Biosciences' Short-term Investments' 5-year high stood at $210.0 million during Q3 2025, with a 5-year trough of $19.6 million in Q3 2023.
  • Moreover, its 5-year median value for Short-term Investments was $73.6 million (2022), whereas its average is $83.0 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 6377.41% in 2023, then skyrocketed by 24009.41% in 2024.
  • Quarter analysis of 5 years shows Assembly Biosciences' Short-term Investments stood at $101.0 million in 2021, then plummeted by 61.2% to $39.2 million in 2022, then soared by 181.71% to $110.4 million in 2023, then tumbled by 33.21% to $73.7 million in 2024, then skyrocketed by 184.83% to $210.0 million in 2025.
  • Its last three reported values are $210.0 million in Q3 2025, $51.0 million for Q2 2025, and $67.6 million during Q1 2025.